These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15244523)

  • 41. Acute promyelocytic leukemia toluidine blue subtype.
    Invernizzi R; Iannone AM; Bernuzzi S; D'Alessio A; Fiamenghi C; Fenoglio C; Rossi A; Bergamaschi G; Ascari E
    Leuk Lymphoma; 1995; 18 Suppl 1():57-60. PubMed ID: 7496356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
    Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
    J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Myeloid/natural killer cell acute leukemia resembling acute promyelocytic leukemia].
    Wang JN; Hou YQ; Zhang LB; Bao HY; Song M; Meng QQ; Fu XC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):830-4. PubMed ID: 23998568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical features and treatment outcomes of pediatric acute promyelocytic leukemia in a Mexican pediatric hospital.
    Dorantes-Acosta E; Medina-Sanson A; Jaimes-García Y; López-Martínez B
    Rev Invest Clin; 2013; 65(5):392-8. PubMed ID: 24687338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement of Early Death in Acute Promyelocytic Leukemia: A Population-Based Analysis.
    Li G; Wu J; Li R; Pan Y; Ma W; Xu J; Nan M; Hou L
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e78-e84. PubMed ID: 36567214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain infarction and blasts with bilobed nuclei in a patient with monocytic acute myeloid leukemia mimicking acute promyelocytic leukemia.
    Elghazaly AA; Ibrahim MH; AlGwaiz LA
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):116-7. PubMed ID: 26802620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?
    Murray CK; Estey E; Paietta E; Howard RS; Edenfield WJ; Pierce S; Mann KP; Bolan C; Byrd JC
    J Clin Oncol; 1999 Jan; 17(1):293-7. PubMed ID: 10458245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis and incidence of acute promyelocytic leukemia (FAB M3 and M3 variant) in childhood.
    Cantú-Rajnoldi A; Biondi A; Jankovic M; Masera G; Rovelli A; Uderzo C; Head D; Raimondi S; Creutzig V; Ritter J
    Blood; 1993 Apr; 81(8):2209-10. PubMed ID: 8471781
    [No Abstract]   [Full Text] [Related]  

  • 49. Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database.
    Guru Murthy GS; Szabo A; Michaelis L; Carlson KS; Runaas L; Abedin S; Atallah E
    J Natl Compr Canc Netw; 2020 Feb; 18(2):169-175. PubMed ID: 32023530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The clinical and laboratory features of acute promyelocytic leukemia: an analysis of 513 cases].
    Liang JY; Wu DP; Liu YJ; Ma QF; Gong JX; Zhu MQ; Xue YQ; Chen ZX
    Zhonghua Nei Ke Za Zhi; 2008 May; 47(5):389-92. PubMed ID: 18953948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The "typical" immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant?
    Exner M; Thalhammer R; Kapiotis S; Mitterbauer G; Knöbl P; Haas OA; Jäger U; Schwarzinger I
    Cytometry; 2000 Apr; 42(2):106-9. PubMed ID: 10797447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute promyelocytic leukemia-associated thrombosis.
    Chang H; Kuo MC; Shih LY; Wu JH; Lin TL; Dunn P; Tang TC; Hung YS; Wang PN
    Acta Haematol; 2013; 130(1):1-6. PubMed ID: 23343825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
    Jeddi R; Hdiji S; Kacem K; Ben Lakhal R; Aissaoui L; Ben Abid H; Belhadj Ali Z; Meddeb B
    Tunis Med; 2006 Nov; 84(11):717-20. PubMed ID: 17294898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants.
    Sucić M; Zadro R; Burazer B; Labar B; Nemet D; Mrsić M; Aurer I; Mrsić S; Hitrec V; Boban D; Marković-Glamocak M; Batinić D; Uzarević B; Stavljenić-Rukavina A
    J Hematother Stem Cell Res; 2002 Dec; 11(6):941-50. PubMed ID: 12590709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
    Schoch C; Schnittger S; Kern W; Lengfelder E; Löffler H; Hiddemann W; Haferlach T
    Hematol J; 2002; 3(5):259-63. PubMed ID: 12391544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes.
    Paietta E; Goloubeva O; Neuberg D; Bennett JM; Gallagher R; Racevskis J; Dewald G; Wiernik PH; Tallman MS;
    Cytometry B Clin Cytom; 2004 May; 59(1):1-9. PubMed ID: 15108165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemia.
    Ojeda-Uribe M; Schneider A; Luquet I; Berceanu A; Cornillet-Lefebvre P; Jeandidier E; Lioure B; Ades L; Mauvieux L; Himberlin C
    Eur J Haematol; 2012 Sep; 89(3):267-72. PubMed ID: 22591288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.
    Kaito K; Katayama T; Masuoka H; Nishiwaki K; Sano K; Sekiguchi N; Hagino T; Kobayashi M
    Clin Lab Haematol; 2005 Oct; 27(5):307-11. PubMed ID: 16178910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients.
    Breccia M; De Propris MS; Minotti C; Stefanizzi C; Raponi S; Colafigli G; Latagliata R; Guarini A; Foà R
    Leuk Res; 2014 Feb; 38(2):194-7. PubMed ID: 24296270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study.
    Paietta E; Andersen J; Gallagher R; Bennett J; Yunis J; Cassileth P; Rowe J; Wiernik PH
    Leukemia; 1994 Jul; 8(7):1108-12. PubMed ID: 8035602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.